All 1 Debates between Julian Sturdy and Martin Caton

Neonicotinoid Pesticides

Debate between Julian Sturdy and Martin Caton
Tuesday 25th January 2011

(13 years, 3 months ago)

Westminster Hall
Read Full debate Read Hansard Text Read Debate Ministerial Extracts

Westminster Hall is an alternative Chamber for MPs to hold debates, named after the adjoining Westminster Hall.

Each debate is chaired by an MP from the Panel of Chairs, rather than the Speaker or Deputy Speaker. A Government Minister will give the final speech, and no votes may be called on the debate topic.

This information is provided by Parallel Parliament and does not comprise part of the offical record

Martin Caton Portrait Martin Caton
- Hansard - - - Excerpts

Most of the research that I have looked at for this debate has been new research done by academic institutions that leads to further worries about the use of this particular group of systemics. I will come on to that in a moment.

Without a completed review of the report, DEFRA decided not to accept Buglife’s interpretation of the current science and continues to maintain that

“We have a robust system for assessing risks from pesticides in the UK”

that is based on evidence. DEFRA goes on to state:

“current evidence shows that…there is not an unacceptable risk to bee health”

from these products. That statement was made as recently as last month. But how robust is a risk assessment regime that takes 16 months to deal with a report? That worries me because things have moved on considerably since the production of the Buglife report. Further scientific evidence has been produced over the past 15 months that strengthens the case. Four significant pieces of published research have emerged during that time. The first is a paper in Ecotoxicology by Nils Dittbrenner. It demonstrates a damaging impact on earthworm growth and activity at field level use of Imidacloprid. Secondly, work by the toxicologist, Dr Henk Tennekes, shows that low-level exposure to neonicotinoids by arthropods over a long time is likely to be as damaging as high exposure over a short time and hence more harmful than had been thought. Thirdly, work done by James Cresswell of Exeter university published in Ecotoxicology makes the case, from various pieces of lab work done by others, that a 6% to 20% reduction in honey bee performance is associated with the use of neonicotinoids. However, none of the field studies used to assess the impact of systemic pesticides would be able to detect a change in performance at that level.

Fourthly, a paper by Cedric Alaux of the French National Institute for Agricultural Research published in Environmental Microbiology demonstrates a clear link between neonicotinoid exposure and increased susceptibility to fatal nosema infections that could threaten pollinators. In addition, there is unpublished work that adds to the picture. One piece of work from the Netherlands shows widespread contamination of water bodies in that country and raises concerns about the impacts on the health of freshwater invertebrate populations. The other, from the USA, was the subject of the lead story in The Independent last Thursday under the headline, “Poisoned Spring”.

In an exclusive, Michael McCarthy, the environment editor of The Independent, revealed work from the US Department of Agriculture’s bee research lab, showing that neonicotinoid pesticides make honey bees far more susceptible to disease—even at tiny doses. Therefore, they have to be in the frame when we consider the causes of the colony collapse disorder that is having a devastating effect on bees around the world.

Julian Sturdy Portrait Julian Sturdy (York Outer) (Con)
- Hansard - -

I congratulate the hon. Gentleman on securing this debate. Everyone in this Chamber, I think, agrees that bee health is a very important issue for the whole environment and for the environmental cycle. He has mentioned a number of factors that affect bee health and he has talked about pests and diseases. Does he not think that we should look at bee health as an overall issue and the impacts that are riding on that, rather than just focus on specific issues?

Martin Caton Portrait Martin Caton
- Hansard - - - Excerpts

That is exactly my case. The evidence against the neonicotinoids now is that they make bees and other pollinating insects more susceptible to diseases, so it is not just one factor. We cannot rule out the effect of these systemic pesticides. That is the mistake that has been made so far.

Dr Jeffrey Pettis and his team at the US Department found that increased disease infection happened even when the levels of the insecticides were so tiny that they could not subsequently be detected in the bees, although the researchers knew that they had been dosed with it. Those findings are completely in line with some of the other research that I have already mentioned. That research evidence from the other side of the Atlantic follows hard on the heels of the “leaked memo” from the US Environmental Protection Agency, which is about a newer neonicotinoid called Clothianidin. It is highly critical of the risk assessment process used in the US. It states:

“Information from standard tests and field studies, as well as incident reports involving other neonicotinoid insecticides, suggest the potential for long term toxic risk to honey bees and other beneficial insects.”

Alarm bells should be ringing by now. Neonicotinoids are a group of relatively new compounds that mimic the insect-killing properties of nicotine. They are neurotoxins, attacking the central nervous system of the invertebrates. They are systemic, which means that they get taken into every part of the plant, including the pollen and nectar. In turn, that means that bees and other pollinating insects can absorb them and carry them back to their nests or hives.

In 2008, total neonicotinoid use in Britain involved more than 2.5 million acres—some quarter of the arable cropland in this country—and they are big earners for the chemical companies that produce them. According to the article in The Independent, the German company Bayer earned more than £500 million from the sale of its top-selling insecticide, Imidacloprid, in 2009, which fits in with the point made by the hon. Member for Brighton, Pavilion (Caroline Lucas). As she said, there is no independent monitoring of the process of gathering and assessing results by the manufacturer. When that is the foundation of the approval system, is it any surprise that we find disparities between the findings of subsequent independent research on this systemic pesticide and the research in its own 2005 draft assessment report?

We need to look again at the approval mechanism for crop protection. In doing so, we should be employing the precautionary principle.